This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Poisoning by other medications and drugs
  • /
  • Differential pharmacology and clinical utility of ...

Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting.

Read time: 1 mins
Published:22nd Feb 2017
Author: Rapoport BL.
Availability: Pay for access, or by subscription
Ref.:Cancer Manag Res. 2017;9:41-50.

Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of many cytotoxic chemotherapy regimens. CINV typically manifests during two well-defined time periods (acute and delayed phases). The acute phase is the first 24 hours after chemotherapy and is largely managed with 5-hydroxytryptamine 3 receptor antagonists. The delayed phase, a 5-day at-risk period during which patients are not often in direct contact with their health care provider, remains a significant unmet medical need. Neurokinin-1 (NK-1) receptor antagonists have demonstrated protection against acute and delayed CINV in patients treated with highly emetogenic chemotherapy and moderately emetogenic chemotherapy when used in combination with a 5-hydroxytryptamine 3 receptor antagonist and dexamethasone. Furthermore, recent data indicate that this protection is maintained over multiple treatment cycles.

Rolapitant, a selective and long-acting NK-1 receptor antagonist, is approved as oral formulation for the prevention of delayed CINV in adults. This review discusses the differential pharmacology and clinical utility of rolapitant in preventing CINV compared with other NK-1 receptor antagonists.


Read abstract on library site

Access full article